Key result
Gene therapy offers a promising approach for the sustained intra-articular expression of therapeutic products in rheumatoid arthritis, avoiding the systemic immune suppression of biological agents.
Why the study?
Biological agents for rheumatoid arthritis often cause systemic immune suppression, prompting interest in gene therapy approaches to deliver genes in a target-specific or inducible manner for sustained intra-articular expression.
Gene therapy offers a promising alternative to biological treatments for rheumatoid arthritis by enabling target-specific or inducible sustained intra-articular expression of therapeutic products.
Requires clinical trials before any role in rheumatoid arthritis; leaves open translation beyond preclinical promise.
Significant advances have been achieved in recent years to ameliorate rheumatoid arthritis (RA) in animal models using gene therapy approaches rather than biological treatments. Although biological agents serve as antirheumatic drugs with suppressing proinflammatory cytokine activities, they are usually accompanied by systemic immune suppression resulting from continuous or high systemic dose injections of biological agents. Therefore, gene transfer approaches have opened an interesting perspective to deliver one or multiple genes in a target-specific or inducible manner for the sustained intra-articular expression of therapeutic products. Accordingly, many studies have focused on gene transferring methods in animal models by using one of the available approaches. In this study, the important strategies used to select effective genes for RA gene therapy have been outlined. Given the work done in this field, the future looks bright for gene therapy as a new method in the clinical treatment of autoimmune diseases such as RA, and by ongoing efforts in this field, we hope to achieve feasible, safe, and effective treatment methods.
No takes yet. Share an insight, caveat, or question.
Zavvar et al. (2019) conducted a review in Rheumatoid arthritis. Gene therapy was evaluated. Gene therapy offers a promising approach for the sustained intra-articular expression of therapeutic products in rheumatoid arthritis, avoiding the systemic immune suppression of biological agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: